Atlassian ups AI ante with Rovo collaborative tool
By Jon Swartz
Rovo builds on Atlassian Intelligence, technology the company debuted a year ago
Count Atlassian Corp. among the recent wave of enterprise-software companies turbocharging their push into generative AI.
On Wednesday, the company (TEAM) unveiled Rovo, collaborative software that helps boost productivity via artificial intelligence with improved search across data, tools and platforms. According to the company, the product adds specialized agents to workflows to handle time-consuming tasks, complete projects and help solve complex problems.
In an interview, Mike Cannon-Brookes, Atlassian's CEO and co-founder, described Rovo as "one of the most important, advanced and ambitious products we have ever shipped."
He added: "[AI] is on the level of the smartphone and what it can do with knowledge, content, text and video."
Rovo builds on Atlassian Intelligence, technology that the company debuted a year ago.
"Teams of the future will be humans and AI agents," said Cannon-Brookes, who became the company's sole CEO following the departure of longtime co-CEO Scott Farquhar in April. That AI-human combination, he said, will put an end to a "gazillion open tabs" and accelerate work for Atlassian's 300,000 customers, which include Domino's Pizza Inc. (DPZ) and Ovo Energy.
Nearly half (47%) of digital workers say they struggle to find the information or data they need to effectively perform their jobs, according to a recent survey by management-consulting company Gartner. Large companies with more than 2,000 employees use over 230 apps on average.
Atlassian joins the conga line of Adobe Inc. (ADBE), Salesforce Inc. (CRM) and other enterprise-software companies that are juicing their AI product portfolios.
-Jon Swartz
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
05-01-24 1200ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing